A Cohort Study Comparing IFX to CS for Moderate to Severe UC
Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · May 6, 2021
Trial Information
Current as of May 20, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • moderately to severely active ulcerative colitis, defined as a total score of 6 to 12 on the Mayo scale (scores range from 0 to 12, with higher scores indicating more severe disease) and a subscore of at least 2 on the endoscopic component of the Mayo scale (subscores on each of the four components of the Mayo scale range from 0 to 3)
- • Patients who had colonic involvement of at least 15 cm
- • Patients who had a confirmed diagnosis of ulcerative colitis at least 3 months before screening and confirmed by Pathology
- Exclusion Criteria:
- • Patients who had previously used any TNF inhibitor
- • Patients who were steroid-dependent or steriod-resistant
- • Patients who had undergone subtotal colectomy or total colectomy
- • Patients who had stoma
About Sixth Affiliated Hospital, Sun Yat Sen University
The Sixth Affiliated Hospital of Sun Yat-sen University is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent academic hospital, it integrates clinical practice with research excellence, fostering collaboration among multidisciplinary teams to enhance medical knowledge and improve patient outcomes. The hospital is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, aiming to contribute to the global scientific community and support the development of new therapies and interventions. With a focus on translational medicine, the Sixth Affiliated Hospital actively engages in pioneering studies that address critical health challenges and promote evidence-based practices in diverse medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guandong, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials